Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Receptor-activating autoantibodies and disease: preeclampsia and beyond.

Xia Y, Kellems RE.

Expert Rev Clin Immunol. 2011 Sep;7(5):659-74. doi: 10.1586/eci.11.56. Review.

2.

Risk factors for very preterm delivery and delivery of very-small-for-gestational-age infants among HIV-exposed and HIV-unexposed infants in Botswana.

Parekh N, Ribaudo H, Souda S, Chen J, Mmalane M, Powis K, Essex M, Makhema J, Shapiro RL.

Int J Gynaecol Obstet. 2011 Oct;115(1):20-5. doi: 10.1016/j.ijgo.2011.04.008. Epub 2011 Jul 20.

PMID:
21767835
3.

Pre-eclampsia in low and middle income countries.

Firoz T, Sanghvi H, Merialdi M, von Dadelszen P.

Best Pract Res Clin Obstet Gynaecol. 2011 Aug;25(4):537-48. doi: 10.1016/j.bpobgyn.2011.04.002. Epub 2011 May 17. Review.

PMID:
21592865
4.

Public health perspectives of preeclampsia in developing countries: implication for health system strengthening.

Osungbade KO, Ige OK.

J Pregnancy. 2011;2011:481095. doi: 10.1155/2011/481095. Epub 2011 Apr 4. Review.

5.

Pregnancy-induced hypertension and preeclampsia: levels of angiogenic factors in malaysian women.

Yelumalai S, Muniandy S, Zawiah Omar S, Qvist R.

J Clin Biochem Nutr. 2010 Nov;47(3):191-7. doi: 10.3164/jcbn.10-27. Epub 2010 Oct 29.

6.

Circulating angiogenic and antiangiogenic factors in women with eclampsia.

Vaisbuch E, Whitty JE, Hassan SS, Romero R, Kusanovic JP, Cotton DB, Sorokin Y, Karumanchi SA.

Am J Obstet Gynecol. 2011 Feb;204(2):152.e1-9. doi: 10.1016/j.ajog.2010.08.049. Epub 2010 Nov 9.

7.

Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies.

Powers RW, Jeyabalan A, Clifton RG, Van Dorsten P, Hauth JC, Klebanoff MA, Lindheimer MD, Sibai B, Landon M, Miodovnik M; Eunice Kennedy Shriver National Institute of Child Health Human Development Maternal-Fetal Medicine Units Network.

PLoS One. 2010 Oct 11;5(10):e13263. doi: 10.1371/journal.pone.0013263.

8.

Antiretroviral regimens in pregnancy and breast-feeding in Botswana.

Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, Makhema J, Moyo S, Thior I, McIntosh K, van Widenfelt E, Leidner J, Powis K, Asmelash A, Tumbare E, Zwerski S, Sharma U, Handelsman E, Mburu K, Jayeoba O, Moko E, Souda S, Lubega E, Akhtar M, Wester C, Tuomola R, Snowden W, Martinez-Tristani M, Mazhani L, Essex M.

N Engl J Med. 2010 Jun 17;362(24):2282-94. doi: 10.1056/NEJMoa0907736.

9.

The implications of autoimmunity and pregnancy.

Borchers AT, Naguwa SM, Keen CL, Gershwin ME.

J Autoimmun. 2010 May;34(3):J287-99. doi: 10.1016/j.jaut.2009.11.015. Epub 2009 Dec 23. Review.

PMID:
20031371
10.

Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity.

Siddiqui AH, Irani RA, Blackwell SC, Ramin SM, Kellems RE, Xia Y.

Hypertension. 2010 Feb;55(2):386-93. doi: 10.1161/HYPERTENSIONAHA.109.140061. Epub 2009 Dec 7.

11.

Obstetric and newborn infant outcomes in human immunodeficiency virus-infected women who receive highly active antiretroviral therapy.

Haeri S, Shauer M, Dale M, Leslie J, Baker AM, Saddlemire S, Boggess K.

Am J Obstet Gynecol. 2009 Sep;201(3):315.e1-5. doi: 10.1016/j.ajog.2009.06.017.

PMID:
19733286
12.

The safety of highly active antiretroviral therapy for the HIV-positive pregnant mother and her baby: is 'the more the merrier'?

Martin F, Taylor GP.

J Antimicrob Chemother. 2009 Nov;64(5):895-900. doi: 10.1093/jac/dkp303. Epub 2009 Aug 25. Review.

PMID:
19706669
13.

Maternal infection and risk of preeclampsia: systematic review and metaanalysis.

Conde-Agudelo A, Villar J, Lindheimer M.

Am J Obstet Gynecol. 2008 Jan;198(1):7-22. doi: 10.1016/j.ajog.2007.07.040. Review.

PMID:
18166297
14.

Angiogenic factors for the prediction of preeclampsia in high-risk women.

Moore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE.

Am J Obstet Gynecol. 2007 Sep;197(3):244.e1-8.

PMID:
17826405
15.

Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia.

Vatten LJ, Eskild A, Nilsen TI, Jeansson S, Jenum PA, Staff AC.

Am J Obstet Gynecol. 2007 Mar;196(3):239.e1-6.

PMID:
17346536
16.

Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.

Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA; CPEP Study Group.

N Engl J Med. 2006 Sep 7;355(10):992-1005. Erratum in: N Engl J Med. 2006 Oct 26;355(17):1840.

17.

Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia.

Robinson CJ, Johnson DD, Chang EY, Armstrong DM, Wang W.

Am J Obstet Gynecol. 2006 Jul;195(1):255-9. Epub 2006 Apr 21.

PMID:
16813756
18.

WHO analysis of causes of maternal death: a systematic review.

Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF.

Lancet. 2006 Apr 1;367(9516):1066-74. Review.

PMID:
16581405
19.

Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis.

Masuyama H, Suwaki N, Nakatsukasa H, Masumoto A, Tateishi Y, Hiramatrsu Y.

Am J Obstet Gynecol. 2006 Feb;194(2):551-6.

PMID:
16458660
20.

Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy.

Suy A, Martínez E, Coll O, Lonca M, Palacio M, de Lazzari E, Larrousse M, Milinkovic A, Hernández S, Blanco JL, Mallolas J, León A, Vanrell JA, Gatell JM.

AIDS. 2006 Jan 2;20(1):59-66.

PMID:
16327320

Supplemental Content

Support Center